**Mycobacterium kansasii** Pneumonia with Mediastinal Lymphadenitis in a Patient with Acute Myeloid Leukemia: Successful Treatment to Stem Cell Transplantation

Yeon-Geun Choi¹, Sung-Yeon Cho¹², Dong-Gun Lee¹²³, Eunjung Yim¹, Hyonsoo Joo¹, Seongyul Ryu¹, Jae-Ki Cho¹², and Hee-Je Kim³

¹Division of Infectious Diseases, Department of Internal Medicine, ²Vaccine Bio Research Institute, ³The Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea

Non-tuberculous mycobacterial (NTM) disease is a relatively rare cause of neutropenic fever in patients with hematologic malignancies. During the neutropenic period, performing invasive procedures for microbiological or pathological confirmation is difficult. In addition, the optimal treatment duration for NTM disease in patients with leukemia, especially prior to stem cell transplantation (SCT), has not been documented. Therefore, we report a case of pneumonia with necrotizing lymphadenitis caused by *Mycobacterium kansasii* diagnosed during chemotherapy being performed for acute myeloid leukemia. The radiologic findings were similar to those of invasive fungal pneumonia; however, a bronchoalveolar washing fluid culture confirmed that the pathogen was *M. kansasii*. After 70 days from starting NTM treatment, allogeneic SCT was performed without any complications. The patient fully recovered after 12 months of NTM treatment, and neither reactivation of *M. kansasii* infection nor related complications were reported.

**Key Words:** *Mycobacterium kansasii*; Lymphadenitis; Pneumonia; Leukemia, Myeloid, Acute; Stem cell transplantation

**Introduction**

Non-tuberculous mycobacteria (NTM) are mycobacteria other than *Mycobacterium tuberculosis* complex and *Mycobacterium leprae*. NTM are ubiquitous organisms, which are frequently isolated from environmental sources, including surface water, tap water, and soil [1, 2]. NTM disease is closely related to a host's immune status. The most common manifestation of human NTM infection is lung disease, especially in patients with bronchiectasis or chronic obstructive pulmonary disease. Disseminated infections can also develop in immunocompromised patients such as human immunodefi-
ciency virus-infected patients [3]. *Mycobacterium kansasii* is one of the slow growing NTM species that constitutes only 2–4% of all NTM organisms isolated from clinical specimens; however, *M. kansasii* is the second most common species that cause NTM lung disease in the United States and Japan [3, 4]. In Korea, *M. kansasii* is relatively uncommon, which accounts for only 2% of the NTM lung disease [5, 6]. While *M. kansasii* usually involves the lungs, concomitant lymphadenopathy or pleural effusion have been rarely documented [7].

Resistant organisms, nonbacterial infections (*i.e.*, fungal or viral), unresolved infection foci (*i.e.*, abscess, catheter), and non-infectious fevers (*i.e.*, drug fever or metabolic fever) are documented causes of persistent neutropenic fever [8]. Since NTM disease is a rare cause of neutropenic fever, the diagnosis can be often delayed in hematologic patients. The recommended treatment duration for pulmonary *M. kansasii* disease is at least 12 months if sputum cultures are negative [3]. However, the treatment duration should be individualized according to each patient’s immune status and clinical course of NTM disease [3]. In patients with acute leukemia, the optimal duration of NTM treatment prior to stem cell transplantation (SCT) has not been documented.

Here, we describe the successful treatment of a case of *M. kansasii* pneumonia with necrotizing lymphadenitis mimicking invasive fungal pneumonia that developed in an acute myeloid leukemia (AML) patient. This study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital at the Catholic University of Korea with a waiver of informed consent (Subject number: KC15RISE0399).

**Case Report**

A 46-year-old man diagnosed with AML underwent induction chemotherapy with cytarabine 100 mg/m² for 7 days and idarubicin 12 mg/m² for 3 days. On day 10 after induction chemotherapy, neutropenic fever developed (axillary temperature of up to 38.3°C). No other symptoms were reported. Laboratory data showed a white blood cell (WBC) count of 150/ mm³ (absolute neutrophil count [ANC] 0/mm³) and C-reactive protein (CRP) level of 0.33 mg/dL. Liver enzymes were within their normal ranges. Chest X-ray was normal and no definite infection focus was noted during the physical examination. Cefepime (2 g twice/day) and isepamicin (400 mg once/day) was started empirically and posaconazole prophylaxis (200 mg 3 times/day) was continued. On day 14, cefepime was changed to imipenem/cilastatin (500 mg 4 times/day) due to persistent neutropenic fever. On day 20, ANC was still 0/mm³ and fever persisted despite broad-spectrum antibiotics. Posaconazole prophylaxis was stopped and amphotericin B deoxycholate (1 mg/kg/day) was started.

On day 25, the patient had recovered from neutropenia (WBC 11,930/mm³; ANC 7,160/mm³), but the chest X-ray showed new infiltrates in the left hilar area. Low dose chest computed tomography (CT) was performed, which showed a 3.7 cm diameter, ill-defined, round consolidation with adjacent ground-glass opacity (Fig. 1A). Repeated serum galactomannan assays performed twice per week were consistently negative during the hospital stay. Although the pathogen had not yet been identified, it met the criteria for possible category of invasive fungal pneumonia as defined by the European Organization for the Research and Treatment of Cancer/Mycoses Study Group [9]. On day 33, the fever subsided, and amphotericin B deoxycholate was changed to oral itraconazole capsules (200 mg twice/day). The patient was discharged with itraconazole, which was maintained until next admission episode for consolidation chemotherapy. The patient’s clinical course is presented in Figure 2.

Before starting consolidation chemotherapy, follow-up enhanced chest CT showed increased size of consolidation (3.7 cm → 4.1 cm diameter) with newly noted right paratracheal necrotizing lymphadenitis (4.5 cm diameter) (Fig. 1B, C). Itraconazole was changed to amphotericin B deoxycholate (1 mg/kg/day), and a bronchoscopy was performed to identify the pathogen. Necrotic mucosal change was noted at a superior segment of left lower lobe (LLL) bronchus. Bronchial washing from LLL bronchus and a biopsy at the necrotic lesion was performed. The bacterial culture, fungus culture, concentration of acid-fast bacilli, and tuberculosis polymerase chain reaction (PCR) from the bronchial washing fluid were all negative. In the pathology specimen, chronic granulomatous inflammation without caseous necrosis was observed. The Ziehl-Neelsen stain and tissue PCR for *M. tuberculosis* were negative. The patient began receiving consolidation chemotherapy (cytarabine 2 g/m² for 5 days and idarubicin 12 mg/m² for 3 days) while continuing amphotericin B deoxycholate. Fifteen days after consolidation chemotherapy, the growth of NTM from the bronchial washing fluid was reported. The growth was confirmed as *M. kansasii* via PCR method (Geno-Type Mycobacterium CM assay, Hain Lifescience, Nehren, Germany). Therefore, oral isoniazid (300 mg/day), rifampicin (600 mg/day), and ethambutol (800 mg/day) were started. Approximately 2 months later, follow-up chest CT showed a decrease in the size of left hilar lesion (4.1 cm to 2.2 cm) and
After 70 days of anti-NTM therapy, allogeneic SCT was successfully completed without acute complications. Antimicrobial susceptibility testing for *M. kansasii* revealed susceptibility to rifampicin. Anti-NTM medications were continued in addition to cyclosporine for immunosuppression after SCT. At post-SCT day 56, a blood chemistry test revealed an aspartate aminotransferase (AST) level of 180 IU/L, an alanine aminotransferase (ALT) of 207 IU/L, and a total bilirubin level of 5.49 mg/dL. The cyclosporine drug level was below 50 ng/mL. After changing rifampicin to rifabutin (450 mg/day), AST/ALT, and total bilirubin were normalized and cyclosporine drug levels were in therapeutic range.

During anti-NTM therapy, fever and respiratory symptoms were not noted. Chest CT performed 6 months post anti-NTM therapy showed interval regression (Fig. 1D, E). Furthermore, *M. kansasii* was not isolated from the respiratory specimen after starting NTM treatment. After 12 months of anti-NTM treatment, the patient achieved complete resolution of NTM diseases with clinical, radiologic, and microbiological improvement. He did not experience reactivation of the *M. kansasii* infection nor related complications. In addition, complications related to SCT, such as graft-versus-host disease or cytomegalovirus reactivation, were not reported.

**Discussion**

In this case report, *M. kansasii* disease was diagnosed during chemotherapy for AML. Initial CT findings indicated invasive fungal pneumonia, which may have resulted in a delayed diagnosis of NTM lung disease. After 70 days of treatment with isoniazid, rifampicin, and ethambutol, the patient successfully received SCT and recovered without any complications.

NTM is a very rare cause of fever in leukemic patients during chemotherapy [10]. *M. kansasii* is known to cause pneumonia, skin infection, or disseminated infection while it has not been commonly documented to cause lymphadenitis [7, 11, 12]. Hil- lary or mediastinal lymphadenopathies have been found in only 8% of patients with *M. kansasii* lung disease, and the most common pulmonary radiographic findings are nodules and
consolidation [6]. There have been several case reports of *M. kansasii* infection in hematologic patients; 6 cases in hairy cell leukemia patients, 1 in a chronic myelogenous leukemia patient, 1 in chronic lymphocytic leukemia patient, 1 in a follicular lymphoma patient, and 1 in a hemophagocytic syndrome patient [13-16]. Of these 10 cases, 6 cases were disseminated infection with lung involvement, 2 cases were pneumonia, and 2 cases were skin infection [13-16].

The American Thoracic Society guidelines for the treatment of NTM disease caused by *M. kansasii* recommend a 3-drug regimen of rifampicin, isoniazid, and ethambutol [3]. However, few studies have examined the optimal management for *M. kansasii* in hematologic patients who need repetitive chemotherapy or SCT. In addition, the optimal duration of anti-NTM medication, both prior to SCT and post-SCT, has not been documented for patients with leukemia. One study has reported that SCT administered after 100 days of anti-TB medication may be feasible and safe for treating tuberculosis in patients with various hematologic diseases [17].

In this case, the patient had left hilar consolidation and right mediastinal lymphadenitis. However, bronchoscopic biopsy was performed at the necrotic lesion of left bronchus alone. Our patient’s radiologic finding was not the typical finding of *M. kansasii* lung disease described in the ATS/IDSA guidelines, but there are reports that *M. kansasii* lung disease presented as consolidation as well as nodules, cavitation, or bronchiectasis [3, 6]. Based on the positive culture for NTM from bronchial washing fluid, and granuloma from the pathology specimen of left bronchus, the patient could be diagnosed as NTM lung disease [3]. However, transbronchial aspiration of right mediastinal necrotic LN should have been considered to differentiate other concomitant causes, such as fungus, *M. tuberculosis*, or other rare pathogens. The patient suffered from neutropenic fever before anti-NTM diagnosis. However, the clinical symptoms and radiological findings dramatically improved after 2 months of treatment with a 3-drug NTM regimen. In addition, interferon-γ release assays (IGRA), which cannot be used for diagnosis of tuberculosis, was negative in our patients. Negative predictive value for pulmonary tuberculosis of IGRA is known to be 91% - 99% [18, 19]. Repetitive aspergillic antigen tests were also negative in this case. Our patient initially received rifampicin; however, this was changed to rifabutin due to the metabolic interaction in the cytochrome P-450 system [20].

To our knowledge, this is the first report of an *M. kansasii* infection that developed before SCT in an AML patient. Clinicians should be aware that the active diagnostic efforts for pathological or microbiological confirmation could be essential during neutropenia, especially in cases with persistent neutropenic fever. In conclusion, we present here a case of pneumonia with necrotizing lymphadenitis caused by *M. kansasii* that developed during the period of febrile neutropenia after chemotherapy for AML. Although the initial lesion looked like invasive fungal pneumonia, the clinical presentation dif-
ferred. The patient recovered from NTM without reactivation and experienced no complications related to SCT. This case demonstrates the guidance of scheduling SCT in addition to simultaneous NTM treatment. However, additional clinical experience and prospective studies are necessary to determine the optimal treatment of M. kansasii-associated NTM disease during chemotherapy or SCT.

Conflicts of Interest
No conflicts of interest.

ORCID
Sung-Yeon Cho http://orcid.org/0000-0001-5392-3405
Yeon-Geun Choi http://orcid.org/0000-0002-7267-1060

References
1. Anonymous. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156:S1-25.
2. Holland SM. Nontuberculous mycobacteria. Am J Med Sci 2001;321:49-55.
3. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Isman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
4. O’Brien RJ. The epidemiology of nontuberculous mycobacterial disease. Clin Chest Med 1989;10:407-18.
5. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-8.
6. Park HK, Koh WJ, Shim TS, Kwon OJ. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J 2010;51:552-6.
7. Shitrit D, Baum GL, Priess R, Lavy A, Shitrit AB, Raz M, Shlomi D, Daniele B, Kramer MR. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006;129:771-6.
8. Lee DG, Kim SH, Kim SY, Kim CJ, Min CK, Park WB, Park YJ, Song YG, Jang JS, Jang JH, Jin JY, Choi JH. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Infect Chemother 2011;43:258-321.
9. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bill J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
10. Arlotta A, Cefalo MG, Maurizi P, Ruggiero A, Dodi I, Riccardi R. Critical pulmonary infection due to nontuberculous mycobacterium in pediatric leukemia: report of a difficult diagnosis and review of pediatric series. J Pediatr Hematol Oncol 2014;36:66-70.
11. Shitrit D, Priess R, Peled N, Bishara G, Shlomi D, Kramer MR. Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome. Eur J Clin Microbiol Infect Dis 2007;26:679-84.
12. Park SY, Lee GR, Min JW, Jung JY, Jeon YD, Shin HS, Chin BS. A case of Mycobacterium kansasii lymphadenitis in HIV-infected patient. Infect Chemother 2012;44:526-9.
13. Goldschmidt N, Nusair S, Gural A, Amir G, Izhar U, Laxer U. Disseminated Mycobacterium kansasii infection with pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Am J Hematol 2003;74:221-3.
14. Tempero MA, Smith PW. Disseminated Mycobacterium kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. Med Pediatr Oncol 1981;9:283-8.
15. Lyons J, Vandenbergh E, Fahy R, McDonnell C, Keane J, McLaughlin AM. An unusual lung mass post stem cell transplantation. Transpl Infect Dis 2014;16:672-5.
16. Chou YH, Hsu MS, Sheng WH, Chang SC. Disseminated Mycobacterium kansasii infection associated with he-
mophagocytic syndrome. Int J Infect Dis 2010;14:e262-4.
17. Eom KS, Lee DG, Lee HJ, Cho SY, Choi SM, Choi JK, Kim YJ, Lee S, Kim HJ, Cho SG, Lee JW. Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experience. Transpl Infect Dis 2015;17:73-9.
18. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunsch R, Bogyi M, Bothamley G, Bothe C, Codecasa L, Costa P, Dominguez J, Duarte R, Flöe A, Fresard I, García-Garcia JM, Goletti D, Halm P, Hellwig D, Henninger E, Heykes-Udlen H, Horn L, Kruczek K, Latorre I, Pache G, Rath H, Ringshausen FC, Ruiz AS, Solovic I, Souza-Galvão ML, Widmer U, Witte P, Lange C; TBNET. Risk assessment of tuberculosis in contacts by IFN-gamma release assays. A tuberculosis network European trials group study. Am J Respir Crit Care Med 2015;191:1176-84.
19. Lee J, Lee SY, Yoo SS, Cha SI, Won DI, Park JY, Lee WK, Kim CH. Clinical value of whole-blood interferon-gamma assay in patients with suspected pulmonary tuberculosis and AFB smear- and polymerase chain reaction-negative bronchial aspirates. Diagn Microbiol Infect Dis 2012;73:252-6.
20. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92.